AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32213899
Drug: Casein hydrolysate
RxNorm normalized name: casein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein hydrolysate (5 g)
Trial: 32764872
Drug: Collagenase Clostridium
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase Clostridium histolyticum (CCH) 0.58 mg
Trial: 36122258
Drug: Nefopam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (20 mg over 30 minutes, continuous infusion for 24 hours)
Trial: 34425501
Drug: Medical cannabis/cannabis-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical cannabis/cannabis-based medicine (MC/CBM)
Trial: 32915972
Drug: 10-day decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-day decitabine combined with ibrutinib (560 mg; sequentially given, starting the day after the last dose of decitabine) (n = 72)
Trial: 36316826
Drug: Probiotic formulation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic formulation with 3 billion CFU (Lactobacillus acidophilus, Bifidobacterium bifidum, Lactobacillus rhamnosus)
Trial: 32943750
Drug: Lomustine in
RxNorm normalized name: Product containing lomustine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomustine in combination with idarubicin and cytarabine
Trial: 32943750
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy without lomustine
Trial: 33260268
Drug: Medical treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatments
Trial: 33449095
Drug: Any aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Any aspirin use
Trial: 35604746
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (OB-bCBCT, HB-bCBCT, OB-PFE)
Trial: 35778479
Drug: Diet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet therapy and 20 mL of coconut oil/day
Trial: 36123169
Drug: COVID-19 vaccines
RxNorm normalized name: Covid-19 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccines
Trial: 33376568
Drug: Delayed rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed rocuronium injections when BIS decreased to <60 after propofol administration (Group PRd)
Trial: 35871088
Drug: Videoconferencing delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videoconferencing delivered cognitive behavior therapy (VCBT) weekly over a 10-week period
Trial: 33339304
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (600 IU daily)
Trial: 34715650
Drug: (−)-OSU6162 30-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (−)-OSU6162 30-60 mg/day for 12 weeks
Trial: 34715650
Drug: (−)-OSU6162 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (−)-OSU6162 with concomitant antidepressants
Trial: 34715650
Drug: (−)-OSU6162 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (−)-OSU6162 with beta- or calcium-channel blockers
Trial: 34494112
Drug: Plant-based diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant-based diet plus eggs (2 eggs daily)
Trial: 33148972
Drug: β-alanine (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-alanine (6.4 g·d‐1 for 8 wk)
Trial: 32600858
Drug: Partially hydrolysed
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially hydrolysed formula (pHF) with reduced lactose content and Lactobacillus reuteri DSM 17938 (L. reuteri)
Trial: 35895362
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose azithromycin
Trial: 35895362
Drug: 7-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day course of amoxicillin
Trial: 32133778
Drug: Triprolidine 5
RxNorm normalized name: acetaminophen/pseudoephedrine/triprolidine 500 mg-30 mg-1.25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triprolidine 5 mg
Trial: 33752431
Drug: IV catheter
RxNorm normalized name: IV Catheter Plug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV catheter with PosiFlow regulator and infusion clip
Trial: 33752431
Drug: IV catheter
RxNorm normalized name: IV Catheter Plug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV catheter with infusion clip
Trial: 35511285
Drug: Ash‐Kardeh (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ash‐Kardeh (250 g daily for 6 weeks)
Trial: 35151397
Drug: Casirivimab 4
RxNorm normalized name: REGEN-COV, 8-cartons (casirivimab 4, imdevimab 4) (EUA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casirivimab 4 g and imdevimab 4 g administered together in a single intravenous infusion plus usual care
Trial: 33761625
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin for 3 months
Trial: 32448089
Drug: bridging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bridging therapy (intravenous recombinant tissue-type plasminogen activator)
Trial: 35368914
Drug: Human adipose
RxNorm normalized name: HUMAN ADIPOSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human adipose derived mesenchymal stem cells treatment for each 10 cm² of wound
Trial: 32372176
Drug: Subcutaneous testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous testosterone pellet
Trial: 32372176
Drug: Topical testosterone
RxNorm normalized name: testosterone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical testosterone gel
Trial: 32998837
Drug: 2-week online
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week online oral anticoagulant counseling training
Trial: 32568367
Drug: Placebo (diluent,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (diluent, daily for 12 months)
Trial: 34001750
Drug: Single-dose (SGD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose (SGD) containers
Trial: 33831950
Drug: Continuous energy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous energy restriction (CER) - daily, 1500 kcal (6000 kJ)
Trial: 37951954
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg)
Trial: 32578850
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg once daily for 12 months
Trial: 34800700
Drug: Immunotherapy (durvalumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (durvalumab plus tremelimumab)
Trial: 34800700
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus immunotherapy (durvalumab plus tremelimumab)
Trial: 33314886
Drug: Carbohydrate-protein supplement
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-protein supplement (2:2 ratio)
Trial: 33314886
Drug: Carbohydrate-protein supplement
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-protein supplement (3:1 ratio)
Trial: 34992867
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin chemotherapy (40 mg/m2/cycle, 5 cycles)
Trial: 32534369
Drug: Hydroxychloroquine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine and azithromycin (first-choice treatment)
Trial: 32750502
Drug: Upfront combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront combination therapy with fluoropyrimidine (FP), irinotecan (Iri), and bevacizumab (Bev)
Trial: 32750502
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with FP and Bev followed by escalation to Iri, FP, and Bev
Trial: 35653145
Drug: Abemaciclib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib (150 mg, twice daily) plus endocrine therapy (ET) for 2 years
Trial: 32554173
Drug: Web-version of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-version of Prolonged Exposure (Web-PE) therapy
Trial: 34992553
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy conducted by trained music therapists
Trial: 34992553
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy and Music listening
Trial: 36473717
Drug: Lavandula essential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavandula essential oil (LEO) - 5 drops of 20% LEO inhaled for three consecutive days, intervention performed every 24 hours.
Trial: 36473717
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 5 drops of distilled water inhaled for three consecutive days, intervention performed every 24 hours.
Trial: 35633027
Drug: Levetiracetam 1000
RxNorm normalized name: levetiracetam 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 1000 mg bid (starting dose 500 mg) for 12 weeks
Trial: 35351020
Drug: Umbilical cord
RxNorm normalized name: Sus Scrofa Umbilical Cord
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbilical cord blood mononuclear cells (UCB-MNCs) administered via intrathecal route (5 × 10^6 /kg)
Trial: 34016436
Drug: OnTrack application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnTrack application for medication management
Trial: 34016436
Drug: Conventional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medication management
Trial: 36116392
Drug: Aspirin 80
RxNorm normalized name: aspirin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 80 mg
Trial: 35152576
Drug: Acupoint thread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint thread embedding therapy with PGLA thread applied to acupoints (Tianshu, Zhongwan, Ganshu, Shuidao) once every 2 weeks for 12 weeks.
Trial: 32271377
Drug: Durvalumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (20 mg/kg every 4 weeks)
Trial: 32271377
Drug: Durvalumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab plus tremelimumab (20 mg/kg durvalumab + 1 mg/kg tremelimumab every 4 weeks, up to 4 doses)
Trial: 32770384
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (GnRHant) with estradiol add‐back
Trial: 616484288
Drug: 2nd line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2nd line treatments (combining or updosing AHs)
Trial: 33258890
Drug: THC-dominant cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC-dominant cannabis (13.75 mg)
Trial: 33258890
Drug: THC/CBD-equivalent cannabis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC/CBD-equivalent cannabis (13.75 mg)
Trial: 33258890
Drug: CBD-dominant cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD-dominant cannabis (13.75 mg)
Trial: 32804837
Drug: Allicin-containing quadruple
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allicin-containing quadruple therapy (IDFA)
Trial: 32804837
Drug: Bismuth-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-containing quadruple therapy (IDFB)
Trial: 33468340
Drug: Gel pad
RxNorm normalized name: Zenphor Gel Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel pad
Trial: 33167952
Drug: Narrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative medicine training
Trial: 36155119
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (500 mg/day for 90 days)
Trial: 33285347
Drug: Evidence-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based therapy
Trial: 34539185
Drug: Colchicine and
RxNorm normalized name: colchicine and probenecid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine and Standard treatment
Trial: 34296544
Drug: GEMOX-T (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEMOX-T (gemcitabine 1000 mg/m² and oxaliplatin 50 mg/m² on day 1 and day 8 plus erlotinib 100 mg daily for 3 weeks)
Trial: 34296544
Drug: GT (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GT (gemcitabine 1000 mg/m² on day 1 and day 8 plus erlotinib 100 mg daily for 3 weeks)
Trial: 35881893
Drug: Oral sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sildenafil (0.5‐2 mg/kg/6 hours)
Trial: 34337072
Drug: Insulin titration
RxNorm normalized name: INSULIN TITRATION ORAL INHL KIT 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin titration goal of FBG≤5.6 mmol/L
Trial: 34337072
Drug: Insulin titration
RxNorm normalized name: INSULIN TITRATION ORAL INHL KIT 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin titration goal of FBG≤7.0 mmol/L
Trial: 34907633
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for COVID-19
Trial: 37952928
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin A supplementation
Trial: 35398532
Drug: Fidaxomicin (FDX)
RxNorm normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fidaxomicin (FDX) 200 mg twice daily for 10 days
Trial: 35398532
Drug: Vancomycin (VAN)
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin (VAN) 125 mg four times daily for 10 days followed by a 3-week vancomycin taper and pulse (VAN-T/P) regimen
Trial: 33975993
Drug: Denosumab-biosimilar (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab-biosimilar (60 mg subcutaneous every 6 months for 1 year)
Trial: 32533723
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) 1 mg/kg
Trial: 32533723
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) 0.3 mg/kg
Trial: 34167868
Drug: Alendronate (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (35 mg) administered orally every week for 8 weeks
Trial: 34167868
Drug: Alendronate (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (35 mg)
Trial: 33482894
Drug: Oral melatonin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin, 3 mg/kg/day for 15 days
Trial: 32369655
Drug: 1% Acetyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Acetyl zingerone (AZ) applied twice daily for 8 weeks
Trial: 32369655
Drug: Placebo (vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle base cream) applied twice daily for 8 weeks
Trial: 34752019
Drug: BNT162b2 vaccine
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 vaccine (10 μg, 2 doses, administered 21 days apart)
Trial: 32747975
Drug: TAS‐303 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS‐303 18 mg
Trial: 35460165
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of trazpiroben 25 mg (treatment A)
Trial: 35726033
Drug: 800 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU/day of oral vitamin D3
Trial: 35726033
Drug: 400 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU/day of oral vitamin D3
Trial: 33302976
Drug: Nebulised surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised surfactant (Bovactant, Alveofact®) administered at varying doses (10 vials at 0, 8, and 24 hours or 30 vials at 24 hours)
Trial: 33683076
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives (COCs) and laser hair removal
Trial: 33683076
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and laser hair removal
Trial: 33310565
Drug: Bilateral cochlear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral cochlear implants (CIs) on
Trial: 33310565
Drug: Bilateral cochlear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral cochlear implants (CIs) off
Trial: 32432695
Drug: Wait list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait list control (treatment as usual for 8 weeks)
Trial: 32623510
Drug: Bencycloquidium bromide
RxNorm normalized name: Potassium Bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bencycloquidium bromide nasal spray (BCQB)
Trial: 33359277
Drug: Overall population
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall population with RAS inhibitors
Trial: 32729763
Drug: Moderate exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate exercise after α/β adrenergic blocker (labetalol, 100 mg orally)
Trial: 32729763
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion for 20 minutes
Trial: 33259643
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein pre-meal (20 g)
Trial: 38336815
Drug: Placebo suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppository
Trial: 33657970
Drug: Neurological music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurological music therapy (2 times/week, 60 min/session for 3 months)
Trial: 32535812
Drug: Selatinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selatinib (500 mg)
Trial: 32453393
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (2000 IU daily for 6 months)
Trial: 32453393
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1000 mg daily for 6 months)
Trial: 32388522
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (placebo)
Trial: 33484479
Drug: Oral probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotic therapy (Lactobacillus fermentum CECT5716)
Trial: 34602460
Drug: sl‐wIRAR treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sl‐wIRAR treatment (2 treatments/day for 30 min each for 6 days)
Trial: 32224045
Drug: Disease flare
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease flare during tapering of DMARDs
Trial: 34844641
Drug: Magnesium supplements
RxNorm normalized name: Magnesium supplements, alimentary tract and metabolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplements
Trial: 33150703
Drug: Rehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation therapy and risperidone
Trial: 36501070
Drug: Betaine anhydrous
RxNorm normalized name: Betaine Anhydrous
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine anhydrous (BET) 6 g/day for 14 days
Trial: 32130742
Drug: Treatment 1
RxNorm normalized name: CVS Acne Treatment 10% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 1
Trial: 32749941
Drug: Combined adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined adjuvant chemotherapy and radiotherapy (CTRT)
Trial: 35291433
Drug: Melatonin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (10 mg)
Trial: 32985001
Drug: Fermented barley
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented barley - wheat flour compound noodle (FBWN)
Trial: 32869580
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with Hydroprednisone (2 mg•kg‐1•d‐1)
Trial: 32035708
Drug: Tetravalent Inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent Inactivated Influenza Vaccine (TIV)
Trial: 32653075
Drug: High-dose MF–IND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose MF–IND (320 μg, 150 μg) once daily
Trial: 34650220
Drug: Prediction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction of month 7-8 post-treatment retinal sensitivity from baseline SD-OCT data
Trial: 32779505
Drug: Epeleuton 2
RxNorm normalized name: Epeleuton
DrugBank: Epeleuton (DB18100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epeleuton 2 g/day
Trial: 615730633
Drug: Parenteral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral diazepam bolus
Trial: 615730633
Drug: Parenteral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral diazepam continuous infusion
Trial: 615730633
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (bolus and infusion)